A high-concentration CBD product is legal in France under one main condition: the finished product must contain a maximum of 0.3% THC, and the original plant must belong to a hemp variety listed in the European catalogue. The CBD content itself, whether it is 20%, 40%, or more, is not the determining factor for legality. It is compliance with the THC threshold and, for ingested products, with the Novel Food Regulation that determines marketing authorization.
If you own or are considering purchasing high-concentration CBD, here are the priority actions:
- Check that the product is accompanied by a Certificate of Analysis (COA) issued by an accredited laboratory, explicitly stating the THC level in the finished product.
- Check that the hemp variety used is listed in the official catalogue of varieties authorized in Europe.
- Ensure that the product is not presented as a food product without Novel Food authorization (ingestible oils, herbal teas, gummies are particularly monitored).
- Keep the original packaging, proof of purchase and COA, especially in case of inspection.
Pro tip: Photograph the label, the Certificate of Authenticity (COA), and your receipt immediately after purchase and save these documents in a digital folder accessible from your phone. This simple step can make all the difference during a roadside check.
Table of Contents
- The legal framework applicable in France: what laws govern intense CBD?
- Which products with a high concentration of CBD can be marketed in France?
- How to verify the conformity of a high-strength CBD product before buying it?
- What health risks and interactions should be known with intense CBD?
- What to do in case of a traffic stop or police check?
- Where can I buy potent CBD while minimizing risks?
- How to choose a potent CBD product: a practical selection guide
- How does a reputable seller prove the conformity of a high-strength CBD product?
- Key points
- Supplier transparency, an imperative that the market still underestimates
- Thefrenchhempempire: compliant CBD products with complete traceability
- Official sources and useful documents for verifying compliance
The legal framework applicable in France: what laws govern intense CBD?
The legality of CBD in France is based on an overlap of national and European texts whose respective scope deserves to be clarified.
The foundational texts and their scope
The decree of June 22, 2023, constitutes the current regulatory cornerstone: it authorizes the marketing of hemp flowers, leaves, and resins provided that the finished product has a THC content of 0.3% or less and that the variety is listed in the European catalogue. Before this decree, the situation was more restrictive: only fibers and seeds were explicitly authorized, which placed flowers in a legal gray area.
Thedecree of December 30, 2021 had already paved the way by authorizing the sale of dried flowers and leaves under strict conditions, but it was European case law, in particular the ruling of the Court of Justice of the European Union in the Kanavape case (2020), that forced France to align its regulations with the principle of free movement of goods legally produced in another Member State.
For products intended for ingestion, Regulation (EU) 2015/2283 on novel foods applies: CBD is classified as a novel food ingredient, which subjects ingestible oils and other foodstuffs to a prior authorization procedure with the European Food Safety Authority (EFSA). No CBD oil or infusion has yet obtained this widespread approval.
The supervisory authorities and their respective roles
| Authority | Main role | Possible sanctions |
|---|---|---|
| ANSM (National Agency for the Safety of Medicines) | Regulation of CBD-based medicines (e.g., Epidyolex), monitoring of therapeutic claims | Product recall, legal action |
| DGCCRF (Directorate General for Competition Policy, Consumer Affairs and Fraud Control) | Analytical sampling, THC content testing, verification of claims | Fines, seizures, criminal reclassification |
| MILDECA / drogues.gouv.fr | Public information, interministerial coordination on drugs and substances | No power of direct sanctions |
| Ministry of Health / Ameli | Dissemination of precautions for use, regulation of self-medication | Recommendations and warnings |
The DGCCRF's position: products exceeding the 0.3% THC threshold may be reclassified as narcotics, exposing sellers and consumers to criminal penalties. The DGCCRF conducts regular analytical sampling on the market and publishes control reports.
Chronology of key decisions
The Kanavape decision of the CJEU in 2020 marked a turning point, followed by the order of December 2021 and the decree of June 2023. Since May 15, 2026, the French authorities have strengthened the surveillance of CBD products presented as food, targeting in particular ingestible oils and gummies without Novel Food authorization.
Which products with a high concentration of CBD can be marketed in France?
The product category determines the applicable legal regime, regardless of the CBD concentration. A 99% CBD isolate may be legal for cosmetic or vaping use, while a 10% oil intended for oral consumption remains subject to Novel Food authorization.
Flowers and resins
Flowers and resins from varieties listed in the European catalogue are authorized for sale as long as the finished product does not exceed 0.3% THC. These are the least regulated categories, which explains their prevalence on the French market. Legal CBD resins with a high CBD concentration fall under this category, subject to varietal traceability and batch analysis.
E-liquids and vapes
CBD e-liquids and vape cartridges are permitted in France, provided they comply with the THC limit and do not contain any therapeutic claims. Their status is distinct from that of foodstuffs, which excludes them from the Novel Food category.
Regulatory clarification: CBD e-liquid is not considered a food under the Novel Food Regulation, but remains subject to regulations on tobacco products and vaping devices (TPD directive) with regard to the container and flavorings.
Ingestable oils, capsules and gummies
These products are the most subject to regulatory scrutiny. Classified as foodstuffs, they fall under the Novel Food Regulation and cannot be marketed without prior authorization from the EFSA. Since 2026, controls have intensified in this segment, and sellers offering these products without an authorization dossier risk having them withdrawn from the market.
Cosmetics
Cosmetic products containing CBD (creams, balms, massage oils for external use) are not classified as Novel Foods. They are subject to European Cosmetics Regulation (EC) No. 1223/2009, which requires a safety assessment and notification in the CPNP database. The CBD concentration is not capped by this regulation, but the THC level in the finished product must remain within acceptable limits.
Full-spectrum extracts and isolates
Full-spectrum extracts, which contain all the cannabinoids of the plant (CBD, CBG, CBN, CBC, and traces of THC), are legal if the residual THC remains below the regulatory threshold. Pure CBD isolates (crystals, powder) can be used in cosmetic formulations or e-liquids, but their incorporation into food remains subject to Novel Food regulations.
How to verify the conformity of a high-strength CBD product before buying it?
Verifying the conformity of a product with a high concentration of CBD relies on a structured approach, applicable to both consumers and resellers.
Sequential verification steps
- Request the Certificate of Analysis (COA) for the batch in question. A generic or undated COA is not sufficient: it must correspond to the batch number of the product you are purchasing.
- Verify the laboratory's identity. The laboratory must be accredited according to ISO/IEC 17025, which guarantees the reliability of the analytical methods used.
- Check the THC level in the finished product. The value must be less than or equal to 0.3%. A result expressed only on the dry matter, without specifying the finished product, is insufficient.
- Identify the hemp variety. The COA or product sheet must mention the variety used and allow verification of its registration in the European catalogue of authorized varieties.
- Read the labeling information. The label must indicate the CBD and THC content, the recommended use (non-food for flowers/resins/vapes), and must not contain any therapeutic claims such as "relieves pain" or "treats anxiety".
- Check for the absence of unauthorized therapeutic claims. Any mention of a medical effect on a non-medicinal CBD product constitutes a violation of health claims regulations.
What a COA should contain
- Complete cannabinoid profile: CBD, THC, CBG, CBN, CBC with quantified values
- Analytical method used (HPLC, GC-MS or equivalent)
- Limit of detection and limit of quantification for THC
- Batch number and date of analysis
- Laboratory contact information and accreditation
Pro tip: If the seller can't provide a Certificate of Authenticity (COA) matching your product's batch number, consider this a major red flag. A reputable supplier generates a COA for each batch, not a single document valid for an entire product line.
Warning signs to identify
- Complete absence of COA or undated COA
- THC level not specified or expressed ambiguously
- Therapeutic claims on the packaging or product information sheet
- Varietal origin not mentioned
- Unidentifiable or unaccredited analysis laboratory
What health risks and interactions should be known with intense CBD?
A product with a high concentration of CBD is not without side effects, and caution is all the more necessary the higher the dose absorbed.
Documented side effects
The World Health Organization has established that CBD has a good safety profile (critical review report) and is not addictive, but it does report some real side effects: drowsiness, dry mouth, digestive problems (nausea, diarrhea), and changes in appetite. These effects are dose-dependent and more frequent with concentrated products. At-risk populations include pregnant or breastfeeding women, the elderly, and individuals with liver disease.
Drug interactions
CBD inhibits certain cytochrome P450 enzymes, notably CYP3A4 and CYP2C9, which are involved in the metabolism of many common medications: anticoagulants (warfarin), antiepileptics, immunosuppressants, and some antidepressants. This interaction can alter the plasma concentration of the medication in question, with potentially serious clinical consequences. Anyone undergoing medical treatment should consult a healthcare professional before using high-concentration CBD, in accordance with the recommendations of theANSM (French National Agency for Medicines and Health Products Safety) and Ameli (French National Health Insurance).
Inserm warns: clinical research on CBD for the general public remains limited. Most of the available evidence comes from preclinical studies or small trials, which does not allow for the validation of therapeutic effects for pain, sleep, or psychiatric disorders outside of strictly defined medical indications.
Epidyolex and the boundary between medical and non-medical
Epidyolex is the only CBD-based medication authorized in France, indicated for the treatment of certain forms of severe epilepsy (Dravet syndrome, Lennox-Gastaut syndrome). Its use is strictly regulated by medical prescription. Any CBD product sold over the counter cannot claim the same effects or be presented as a therapeutic substitute. The distinction between prescribed medical cannabis and non-medical CBD available without a prescription is fundamental from a regulatory standpoint.
What to do in case of a traffic stop or police check?
The main practical risk for the heavy CBD consumer lies in roadside checks, where currently used saliva tests do not distinguish CBD from THC.
Procedure to follow during an inspection
- Remain calm and cooperate with law enforcement.
- Present the original product packaging, proof of purchase and the COA corresponding to the batch immediately.
- Clearly state that this is a legal CBD product in accordance with the decree of June 22, 2023, with a THC level less than or equal to 0.3%.
- In the event of a positive saliva test, request a confirmatory blood test, which is the only way to distinguish between active THC and CBD.
- If the product is seized, demand a seizure receipt and retain all documents for possible recourse.
The problem with saliva tests
Saliva tests used during roadside checks do not differentiate between CBD and THC, which can lead to a positive result even in the absence of significant amounts of active THC. A CBD product containing legal traces of THC can trigger a positive result. The practical recommendation is not to drive immediately after consuming a CBD product, especially a full-spectrum product.
Pro tip: Keep a digital copy of your Certificate of Authenticity (COA) and proof of purchase on your phone. Being able to present these documents immediately during a check reduces the risk of arbitrary seizure and facilitates discussions with law enforcement.
Anti-doping and travel
For athletes subject to doping controls, the World Anti-Doping Agency (WADA) has removed CBD from its list of prohibited substances, but THC remains banned. A full-spectrum product containing traces of THC can lead to a positive test. For international travel, regulations vary considerably from country to country: carrying a CBD product that is legal in France may be an offense in other jurisdictions. International mailings of CBD are subject to the same customs uncertainties.
Where can I buy potent CBD while minimizing risks?
The purchasing channel directly influences the level of assurance obtained regarding product conformity.
Established specialty shops
Physical stores specializing in CBD offer the advantage of being able to consult Certificates of Analysis (COAs) on-site and ask questions directly to the salesperson. Trustworthy criteria include: the ability to provide a COA for each batch upon request, explicit mention of the hemp variety, and the absence of therapeutic claims on the displayed products.
Transparent online sites
For online purchases, the following criteria indicate reliability: a Certificate of Authenticity (COA) easily accessible on the product page or upon request, complete legal information (SIRET number, physical address), a clear return policy, and precise information on the origin of raw materials. Discreet delivery is common practice among reputable sellers, but it does not replace the need for transparent documentation.
Pharmacies
Some pharmacies offer CBD products, including oils for external use and cosmetics. Their strict regulatory framework provides an additional guarantee, but their selection remains limited in terms of concentration and product variety.
Importation and customs risks
Importing CBD from a country outside the European Union carries significant customs risks, even if the product is legal in the country of origin. French customs applies national regulations, and a product compliant with US or Swiss law may be seized upon entry into France. Purchasing from suppliers established within the European Union remains the safest option.
How to choose a potent CBD product: a practical selection guide
CBD concentration is just one parameter among others to assess the quality and conformity of a product.
- Laboratory transparency: the COA must be issued by an ISO/IEC 17025 accredited laboratory, independent of the manufacturer, with a batch number corresponding to the product purchased.
- Complete cannabinoid profile: a quality product indicates the levels of CBD, THC, CBG, CBN, and CBC. An incomplete profile or one limited to CBD alone should raise a red flag.
- Extraction method: Supercritical CO₂ extraction is the reference method for high concentration products, as it preserves cannabinoids without chemical solvent residues.
- Verifiable varietal origin: the hemp variety must be named and traceable back to the registered seed producer.
- Absence of impurities: the COA must include analyses for pesticides, heavy metals and solvent residues, especially for concentrated extracts.
- Concentration vs. dosage: a more concentrated product isn't necessarily more suitable. The "start with a low dose and gradually increase" rule applies even more so with high-CBD products. To delve deeper into the specific effects of concentrated products, high-concentration CBD details the mechanisms and precautions for use.
- Price relative to quality: an abnormally low price for a high concentration should raise suspicion. The cost of quality extraction and thorough laboratory analysis is reflected in the final price.
How does a reputable seller prove the conformity of a high-strength CBD product?
The conformity of a product with a high concentration of CBD is not based solely on a declaration by the seller: it is demonstrated by a set of verifiable documents and processes.
The supplier journey in practice
A responsible supplier selects its seeds from registered seed producers offering varieties listed in the European catalogue. Crops are registered with the relevant authorities, and analyses are carried out during cultivation to anticipate THC drift. After harvest, each batch undergoes a complete analysis before marketing, generating a batch-specific Certificate of Analysis (COA).
Example of a compliant COA structure
| COA Field | Example value | Meaning |
|---|---|---|
| CBD content (finished product) | — | Effective CBD concentration |
| THC content (finished product) | 0,3 % | Compliant with the legal threshold of 0.3% |
| Analytical method | HPLC-UV | Reference method for cannabinoids |
| THC quantification limit | ≤ 0,3 % | Measurement sensitivity |
| Pesticides | Not detected | Absence of pesticide residues |
| Heavy metals | Compliant with EU thresholds | Food safety verified |
| Batch number | LOT-2026 | Batch-by-batch traceability |
| Date of analysis | May 2026 | Freshness of the analysis |
Traceability must allow tracing the product back to the harvest batch, or even to the field of cultivation. This traceability requirement is precisely what health authorities, particularly the ANSM (French National Agency for Medicines and Health Products Safety), prioritize during inspections: a clear Certificate of Authenticity (COA) associated with a traceable batch substantially reduces the risk of recall or penalty.
Regular checks and audits
The DGCCRF (French Directorate General for Competition Policy, Consumer Affairs and Fraud Control) regularly conducts analytical sampling on the market. A reputable seller anticipates these checks by keeping their compliance records up to date and retaining samples of each batch sold. Compliance practices for potent CBD products also include periodic internal audits and active regulatory monitoring.
Pro tip: Always ask the seller if the Certificate of Authenticity (COA) provided matches the batch number printed on your packaging. A seller who cannot verify this match has no control over their traceability.
Key points
Intense CBD is legal in France as long as the finished product respects the 0.3% THC threshold, the hemp variety is listed in the European catalogue, and the declared use complies with the regulatory status of the product (non-food for flowers/resins/vapes, subject to Novel Food for ingested foodstuffs).
| Point | Details |
|---|---|
| Determining legal threshold | The THC level in the finished product must be less than or equal to 0.3%, regardless of the CBD concentration. |
| Novel Food for the Unmanageable | CBD oils, gummies and herbal teas require Novel Food authorization; their sale without this status is irregular. |
| COA per batch required | Require a certificate of analysis corresponding to the batch number of the purchased product, issued by an ISO/IEC 17025 accredited laboratory. |
| Risk during inspections | Saliva tests do not distinguish between CBD and THC; keeping packaging, proof of purchase and COA reduces the risk of penalty. |
| Thefrenchhempempire | Offers CBD flowers, resins and vapes with COA per batch, varietal traceability and compliance with the 0.3% THC threshold. |
Supplier transparency, an imperative that the market still underestimates
The public debate surrounding CBD often focuses on the question of legality, as if a simple "legal/illegal" answer were enough to protect the consumer. However, the reality of the market is more nuanced: a product can be presented as legal while being non-compliant on essential points, whether it be a generic Certificate of Authenticity not associated with the batch, an unverified variety, or therapeutic claims concealed in the product description.
What a portion of the French market still lacks is not regulation. The laws exist, the 2023 decree is clear, and the regulatory authorities are active. What is lacking is a culture of evidence among some operators, and the consumer's ability to demand it. A buyer who knows how to read a Certificate of Analysis (COA), identify an accredited laboratory, and recognize an unauthorized therapeutic claim is a buyer that unscrupulous sellers cannot deceive.
As Inserm points out, clinical evidence on CBD for the general public remains limited, and the effects often attributed to concentrated products are based more on preclinical studies than on large-scale controlled trials. This does not disqualify the use of CBD, but it does require intellectual honesty, which the best players in the sector have incorporated into their communications. Documentary transparency is not just a regulatory requirement: it is essential for a lasting relationship of trust between sellers and consumers, and the best protection against market withdrawals and criminal penalties.
Thefrenchhempempire: compliant CBD products with complete traceability
For consumers seeking high-concentration CBD products without compromising on compliance, Thefrenchhempempire offers a range of premium CBD flowers, legal CBD resins and vapes, all accompanied by batch analysis certificates issued by accredited independent laboratories.
Each product complies with the 0.3% THC limit in the finished product, with verifiable varietal traceability and labeling compliant with French regulations. No therapeutic claims are made on the product information sheets, in accordance with the requirements of the ANSM (French National Agency for Medicines and Health Products Safety) and the DGCCRF (French Directorate General for Competition Policy, Consumer Affairs and Fraud Control). Discreet and secure delivery is provided throughout Europe.
To view the available range and access the corresponding COAs, go directly to the product pages of Thefrenchhempempire.
Official sources and useful documents for verifying compliance
The resources below allow you to independently verify the applicable regulatory framework and consult the recommendations of the competent authorities.
Priority for consultation: start with Ameli and drogues.gouv.fr for precautions for use and the definition of non-medical CBD, then consult the ANSM for questions relating to medicines and therapeutic claims. For legal texts, the decree of June 22, 2023, and the Novel Food Regulation (EU) 2015/2283 are the primary references.
- Ameli.fr — Non-medical CBD: definition of non-medical CBD, precautions for use, distinction from Epidyolex. A primary reference for consumers.
- Drogues.gouv.fr / MILDECA : situation report on CBD, legal status, information for the general public and professionals.
- ANSM : regulation of CBD-based medicines, monitoring of therapeutic claims, information on Epidyolex.
- Inserm — Canal Détox: critical analysis of the scientific evidence available on CBD, useful for evaluating wellness claims.
- WHO — Critical Review Report on Cannabidiol (CRC): International assessment of the safety profile of CBD, drug interactions and documented adverse effects.
- Regulation (EU) 2015/2283 on novel foods: reference text to understand why ingestible CBD oils and gummies require prior authorization.
- Decree of June 22, 2023: founding text of the current system authorizing the marketing of flowers, leaves and resins under THC conditions.
To maintain proof of conformity, always archive the batch certificate of authenticity (COA), proof of purchase, and original packaging. In the event of a dispute or inspection, these documents form the basis of any recourse and facilitate batch identification with the seller or authorities.
This article provides general educational information on the regulations applicable to CBD in France. It does not constitute legal or medical advice. For any personal situation, consult a healthcare professional or a specialized lawyer, and verify the official regulations in force with the relevant authorities.
